The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | CITADEL-204: safety and efficacy of parsaclisib in R/R MZL
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, discusses the Phase II CITADEL-204 study (NCT03144674) evaluating the safety and efficacy of a potent, highly selective phosphatidylinositol 3 kinase (PI3K) δ inhibitor, parsaclisib, in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL). In a patient cohort naïve to Bruton’s tyrosine kinase (BTK) inhibitors, an overall response rate (ORR) of 57.6% was observed. The response rates were comparable across MZL subtypes including nodal, extranodal or splenic MZL. The interim safety data suggests that parsaclisib is generally well tolerated, with expected toxicities such as neutropenia and diarrhea. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
